LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Genotypic resistance profiles of HIV-2-treated patients in Côte d'Ivoire, West Africa.

Publication

Author(s):

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK; and the IeDEA West Africa Collaboration.

Pub Title:

Genotypic resistance profiles of HIV-2-treated patients in Côte d'Ivoire, West Africa.

Pub Date:

May 15 2014

Pub Region(s):

West Africa

Journal:

Title: 
AIDS
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112041/

PubMed: 24583671
Pub PDF:

Abstract
OBJECTIVE:
To assess the virological response, genotypic resistance profiles, and antiretroviral plasma concentrations in HIV-2 antiretroviral-treated (antiretroviral therapy, ART) patients in Côte d'Ivoire.
 
METHODS: A cross-sectional survey was conducted among HIV-2 patients receiving ART. Plasma HIV-2 viral load was performed using the ANRS assay. Protease and reverse transcriptase sequencing was performed using in-house methods and antiretroviral plasma concentrations were assessed using ultra performance liquid chromatography combined with tandem mass spectrometry.

RESULTS: One hundred forty five HIV-2-treated patients were enrolled with a median CD4 cell count of 360/μl (interquartile range, IQR = 215-528). Median duration of ART was 4 years (IQR = 2-7) and 74% of patients displayed viral load less than 50 copies/ml. Median plasma HIV-2 RNA among patients with viral load more than 50 copies/ml was 3016 copies/ml (IQR = 436-5156). Most patients (84%) received a lopinavir/ritonavir-based regimen. HIV-2 resistance mutations to nucleoside reverse transcriptase inhibitors and protease inhibitors were detected in 21 of 25 (84%) and 20 of 29 (69%) samples, respectively. The most prevalent nucleoside reverse transcriptase inhibitor resistance mutations were M184I/V (90%), Q151M (24%), and S215F/Y (24%). The most prevalent protease inhibitor resistance mutations were V47A (60%) and I54M (30%). Median CD4 cell counts were 434/μl (292-573) and 204/μl (122-281) in patients with viral load less than 50 copies/ml and those exhibiting virological failure (P < 0.0001), respectively. The proportions of patients with adequate antiretroviral plasma concentrations were 81 and 93% in patients displaying virological failure and in those with viral load less than 50 copies/ml, respectively (P = 0.046), suggesting good treatment adherence.

CONCLUSION: We observed adequate drug plasma concentrations and virological suppression in a high proportion of HIV-2-infected patients. However, in cases of virological failure, the limited HIV-2 therapeutic arsenal and cross-resistance dramatically reduced treatment options.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK; and the IeDEA West Africa Collaboration. Genotypic resistance profiles of HIV-2-treated patients in Côte d'Ivoire, West Africa. AIDS. 2014 Feb 27. [Epub ahead of print] PubMed PMID: 24583671.